Efavirenz and nevirapine interactions with rifampicin: Resolving the dilemmas?

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1760-1762

  Lalloo, Umesh G ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; ETHAMBUTOL; ETRAVIRINE; ISONIAZID; LOPINAVIR PLUS RITONAVIR; MOXIFLOXACIN; NEVIRAPINE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RITONAVIR;

DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MENTAL DISEASE; MORBIDITY; MORTALITY; NAUSEA; NEUROTOXICITY; NOTE; PRIORITY JOURNAL; TUBERCULOSIS; VOMITING;

ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; BENZOXAZINES; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; NEVIRAPINE; RIFAMPIN; TUBERCULOSIS;

EID: 66949167790     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599115     Document Type: Note

References (17)

1. Lalloo UG, Pillay S. Managing tuberculosis and HIV in sub-Sahara Africa. Curr HIV/ AIDS Rep 2008;5:132-9.
2. World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing. WHO report 2008. Geneva, Switzerland: WHO, 2008.
3. Gandhi NR, Moll AP, Lalloo UG, et al. Integration of tuberculosis and HIV treatment in rural South Africa: the Sizonqoba Study. J Ac- quir Immune Defic Syndr 2009; 50:37-43.
4. Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196(Suppl 1):S46-51.
5. Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division ofTu- berculosis Elimination. Managing drug interactions in the treatment of HIV-related tuberculosis. 18 May 2008. Available at: http: //www.cdc.gov/tb/TBHIVDrugs/rifam-pin-therapy. htm. Accessed March 2009.
6. Dicks ED, Keating GM. Etravirine. Drugs 2008; 68:2357-72.
7. Borin MT, Chambers JH, Carel BJ, et al. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharm Therap 1997; 61:544-53.
8. Nijland HM, L'Homme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008;22:931-5.
9. Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Ac- quir Immune Defic Syndr 2008; 47:566-9.
10. Gullick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz- containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350: 1850-61.
11. Basson AE, NtsalaM, Martinson N, et al. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2008; 49:538-43.
12. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Center for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
13. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin vs ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-8.
14. Bonora S, Mondo A, Trentini L, et al. Mox- ifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. J Infect 2008;57:78-81.
15. 2R study. Clin Infect Dis 2009;48:1752-9 (in this issue).
16. Friedland G, Khoo S, Jack C, Lalloo UG. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006;58:1299-302.
17. Haas DW, Gebretsadik T, Mayo G et al. Polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis 2009; 199:872-80.